Published by Josh White on 29th June 2021
(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group announced on Tuesday that a study has shown that its 'AffiDX' antigen lateral flow test detects the 'Delta' variant of the SARS-CoV-2 virus in clinical samples.
URL: http://www.digitallook.com/dl/news/story/31950869/...